230 related articles for article (PubMed ID: 34545187)
21. Aristaless Related Homeobox (ARX) Interacts with β-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling.
Cho IT; Lim Y; Golden JA; Cho G
PLoS One; 2017; 12(1):e0170282. PubMed ID: 28103279
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico.
Katoh M; Katoh M
Int J Mol Med; 2003 Oct; 12(4):643-9. PubMed ID: 12964048
[TBL] [Abstract][Full Text] [Related]
23. Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells.
Kotolloshi R; Gajda M; Grimm MO; Steinbach D
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628130
[TBL] [Abstract][Full Text] [Related]
24. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract][Full Text] [Related]
25. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
Sun R; Liu Z; Han L; Yang Y; Wu F; Jiang Q; Zhang H; Ma R; Miao J; He K; Wang X; Zhou D; Huang C
FASEB J; 2019 Apr; 33(4):5411-5424. PubMed ID: 30698996
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of the interaction between BCL9-Pygo and LDB-SSBP complexes in assembling the Wnt enhanceosome.
Wang H; Bienz M; Yan XX; Xu W
Nat Commun; 2023 Jun; 14(1):3702. PubMed ID: 37349336
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure analysis of the PHD domain of the transcription co-activator Pygopus.
Nakamura Y; Umehara T; Hamana H; Hayashizaki Y; Inoue M; Kigawa T; Shirouzu M; Terada T; Tanaka A; Padmanabhan B; Yokoyama S
J Mol Biol; 2007 Jun; 370(1):80-92. PubMed ID: 17499269
[TBL] [Abstract][Full Text] [Related]
28. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of rat Bcl9l gene in silico.
Katoh Y; Katoh M
Int J Oncol; 2005 Mar; 26(3):835-40. PubMed ID: 15703843
[TBL] [Abstract][Full Text] [Related]
30. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.
Yue Z; Yuan Z; Zeng L; Wang Y; Lai L; Li J; Sun P; Xue X; Qi J; Yang Z; Zheng Y; Fang Y; Li D; Siwko S; Li Y; Luo J; Liu M
FASEB J; 2018 May; 32(5):2422-2437. PubMed ID: 29269400
[TBL] [Abstract][Full Text] [Related]
31. Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models.
Mieszczanek J; van Tienen LM; Ibrahim AEK; Winton DJ; Bienz M
Nat Commun; 2019 Feb; 10(1):724. PubMed ID: 30760710
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-590-5p functions as a tumor suppressor in breast cancer conferring inhibitory effects on cell migration, invasion, and epithelial-mesenchymal transition by downregulating the Wnt-β-catenin signaling pathway.
Gao J; Yu SR; Yuan Y; Zhang LL; Lu JW; Feng JF; Hu SN
J Cell Physiol; 2019 Feb; 234(2):1827-1841. PubMed ID: 30191949
[TBL] [Abstract][Full Text] [Related]
33. BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration.
Brack AS; Murphy-Seiler F; Hanifi J; Deka J; Eyckerman S; Keller C; Aguet M; Rando TA
Dev Biol; 2009 Nov; 335(1):93-105. PubMed ID: 19699733
[TBL] [Abstract][Full Text] [Related]
34. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
35. MiR-29b downregulates canonical Wnt signaling by suppressing coactivators of β-catenin in human colorectal cancer cells.
Subramanian M; Rao SR; Thacker P; Chatterjee S; Karunagaran D
J Cell Biochem; 2014 Nov; 115(11):1974-84. PubMed ID: 24913975
[TBL] [Abstract][Full Text] [Related]
36. BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.
Hallas C; Phillipp J; Domanowsky L; Kah B; Tiemann K
BMC Cancer; 2016 Aug; 16():648. PubMed ID: 27539223
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis.
Cai J; Guan H; Fang L; Yang Y; Zhu X; Yuan J; Wu J; Li M
J Clin Invest; 2013 Feb; 123(2):566-79. PubMed ID: 23321667
[TBL] [Abstract][Full Text] [Related]
38. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.
Gay DM; Ridgway RA; Müller M; Hodder MC; Hedley A; Clark W; Leach JD; Jackstadt R; Nixon C; Huels DJ; Campbell AD; Bird TG; Sansom OJ
Nat Commun; 2019 Feb; 10(1):723. PubMed ID: 30760720
[TBL] [Abstract][Full Text] [Related]
39. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
[TBL] [Abstract][Full Text] [Related]
40. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
